focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,775.00
Bid: 1,700.00
Ask: 1,779.00
Change: 0.00 (0.00%)
Spread: 79.00 (4.647%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,775.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LIVE MARKETS-U.S. tax hike less likely: a boon for Europe Inc too

Thu, 05th Nov 2020 10:08

* European shares open higher led by tech

* Strong Q3 earnings reports also help

* Bank of England ramps up stimulus

* Wall Street futures point to more gains
Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You
can share your thoughts with us at markets.research@thomsonreuters.com

U.S. TAX HIKE LESS LIKELY: A BOON FOR EUROPE INC TOO (0957 GMT)

A gridlock in Washington with Biden president and Republicans retaining the Senate is a
scenario that's becoming more likely and equity investors are starting to appreciate the lower
likelihood of business unfriendly policy.

And the possible benefits for corporates, especially on the tax front, are going to be felt
on both sides of the pond.

"President Trump cut the U.S. corporation tax rate from 35% to 21%. The Democrats were
intending to raise it back to 28%. That prospect now seems less likely, which should help U.S.
equities," say Citi strategists.

"It should also boost non-US companies with significant US businesses. Their relative
performance has flat-lined recently," they added.

Several shares in European companies with big presence in the U.S. are doing relatively well
since it emerged that Trump was doing better than expected by the polls.

In the snapshot you can see today's price moves of a basket of European stocks with high
revenue exposure to North America. The basket, which includes names such as Deutsche Telekom
, UBS, Roche and National Grid, is courtesy of Citi.

(Danilo Masoni)

*****

OPENING SNAPSHOT: STRONG Q3, TECH RALLY AND MORE UK STIMULUS (0854 GMT)

European bourses are well in positive territory supported by a batch of positive Q3 results
and more stimulus in the UK as the country starts a second national lockdown.

The pan-European STOXX 600 index is up 0.8% to its highest level since Oct. 20,
with the tech sector leading the gains, up 2.5%.

Britain's blue chips are up 0.3% after the Bank of England increased its already
huge bond-buying stimulus by a bigger-than-expected 150 billion pounds to 895 billion pounds.
The BoE kept the bank rate at 0.1%.

In terms of single companies, Milan-listed Tenaris is set for its best day in 9
years after reporting strong Q3 results, it was last up more than 11%.

(Joice Alves)

*****

ON THE RADAR: BANKS Q3, ARCELORMITTAL, SAINSBURY (0746 GMT)

Looking at futures, it seems like it is going to be a start of the day in the black for
European bourses in a data heavy morning, which also sees investors having to digest a slew of
earnings results.

There is a mixed batch of banking Q3 results with France's third-biggest listed bank Societe
Generale swinging back to profit, as its equity trading business continued to recover
from a weak start to the year; and Italy's second-biggest bank UniCredit posted much
higher than expected net profit as Europe emerged from lockdowns.

In the meantime, Germany's Commerzbank swung to a Q3 loss, as the lender undergoes
a restructuring.

ING Groep, the largest Dutch bank, reported lower than expected pre-tax profit of
1.20 billion euros on declining interest income amid the coronavirus pandemic and said it
intends to cut 1,000 jobs.

British supermarket group Sainsbury also said it could cut 3,500 jobs in a
restructuring.

On a brighter note, ArcelorMittal, the world's largest steelmaker, reported Q3 core
profit above expectations as the easing of lockdowns led to improved demand.
German broadcaster ProSiebenSat.1 Media returned to profit, and reinstated its FY
guidance. Its shares rose 5.7% in premarket trade.

HeidelbergCement, the world's No.2 cement maker, posted a 13% increase in Q3 core
profit, as cost cuts helped it to shrug off the impact of the pandemic and forecast higher
earnings for 2020.

Siemens Gamesa keeps profit target as Q4 uptick fails to stave off loss.

British insurer RSA's underwriting profit rose strongly in the first nine months of
2020 due to improvements the company made to its underwriting strategy.

German reinsurance group Munich Re's net profit declined 77% to 199 million euros
in Q3.

Staying in Germany, specialty chemicals maker Lanxess narrowed its 2020 core
profit outlook range after the coronavirus pandemic, saying it was seeing a pick up in the auto
industry, with China and the U.S. also providing positive stimuli.

While Lufthansa said it booked a net loss of 2 billion euros in Q3.

Sunrise Communications announced plans to boost its 2020 dividend to 4.55 and 4.65
Swiss francs per share, from 4.4 francs, ahead of the Swiss telecommunications firm's takeover
by Liberty Global that will lead to its delisting.

(Joice Alves)

*****

MORNING CALL: STILL NO U.S. PRESIDENT (0638 GMT)

Futures are pointing to gains for European bourses this morning mirroring Asian shares,
which climbed on the prospect that a gridlock in the U.S. Congress will give a boost to some
industries.

So far, the count shows that Democratic challenger Joe Biden narrowly ahead in key states,
but the risk of a prolonged contested election remains.

Back in Europe, it will be a data heavy morning with EZ and UK PMI data due.

The Bank of England's November monetary policy decision is also on schedule. The Telegraph
newspaper reported that the central bank is considering a move into negative interest rates.

(Joice Alves)

*****

More News
4 Apr 2024 00:03

Sanofi to settle 4,000 Zantac cancer lawsuits in US state courts

NEW YORK, April 3 (Reuters) - Sanofi has reached an agreement in principle to settle 4,000 U.S. lawsuits linking the discontinued heartburn drug Zantac to cancer, the company said on Wednesday.

Read more
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 21:37

What to know about bird flu in dairy cows and the risk to humans

CHICAGO, April 3 (Reuters) - Texas officials reported on Monday that a farm worker tested positive for H5N1, or bird flu, that has spread to dairy cows in Texas, Kansas, New Mexico, Michigan and Idaho - the first time the virus has infected cattle.

Read more
19 Mar 2024 09:21

LONDON BROKER RATINGS: Investec cuts ConvaTec; RBC raises Vistry

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
18 Mar 2024 12:00

GSK unveils promising results from endometrial cancer trial

(Sharecast News) - GSK unveiled promising outcomes from a phase three trial of 'Jemperli', or dostarlimab, in treating primary advanced or recurrent endometrial cancer on Monday.

Read more
18 Mar 2024 08:47

TOP NEWS: Pfizer launches GBP2 billion sale of 8% stake in Haleon

(Alliance News) - Haleon PLC on Monday said Pfizer Inc plans to sell around GBP2 billion in Haleon shares, some of which will be bought back by Haleon.

Read more
18 Mar 2024 08:47

GSK says Jemperli combination gets good results for endometrial cancer

(Alliance News) - GSK PLC on Monday said a test of its Jemperli drug in combination with chemotherapy has shown it reduced the risk of death in patients with endometrial cancer by nearly a third.

Read more
7 Mar 2024 09:38

GSK observes positive data in Blenrep trial for blood cancer treatment

(Alliance News) - GSK PLC on Thursday announced positive results for Blenrep for the treatment of multiple myeloma.

Read more
7 Mar 2024 07:21

GSK reports more encouraging trial results for Blenrep

(Sharecast News) - GSK unveiled encouraging results from its 'DREAMM-8' phase three trial on Thursday, comparing the efficacy of 'Blenrep', or belantamab mafodotin, in combination with pomalidomide plus dexamethasone, or PomDex, against the standard treatment of bortezomib plus PomDex in relapsed or refractory multiple myeloma patients.

Read more
5 Mar 2024 11:03

GSK says ViiV's cabotegravir study supports longer HIV dose interval

(Alliance News) - GSK PLC on Tuesday celebrated study results from ViiV Healthcare Ltd, that showed an investigational formulation of cabotegravir can be dosed at four-month intervals.

Read more
5 Mar 2024 07:26

GSK's ViiV upbeat on ultra-long-acting HIV treatment study

(Sharecast News) - GSK announced on Tuesday that its specialist GIV joint venture with Pfizer and Shionogi, ViiV Healthcare, had reported encouraging results from its phase one clinical trial of an investigational formulation of cabotegravir, termed cabotegravir ultra long-acting (CAB-ULA).

Read more
29 Feb 2024 09:44

TOP NEWS: GSK avoids "protracted litigation" with Zantac settlement

(Alliance News) - GSK PLC on Thursday emphasised its commitment to science, as it reached another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
29 Feb 2024 07:22

GSK reaches settlement in another Zantac case

(Sharecast News) - GSK announced a confidential settlement with Boyd/Steenvoord, effectively resolving a case filed in California state court over its discontinued heartburn drug Zantac.

Read more
26 Feb 2024 08:25

GSK gonorrhoea treatment achieves efficacy endpoint in latest trial

(Alliance News) - GSK PLC on Monday announced positive results from the latest trial of its oral gonorrhoea treatment, showing it to be on par with intramuscular therapies.

Read more
26 Feb 2024 07:22

GSK reports positive results from gonorrhoea treatment trial

(Sharecast News) - GSK announced encouraging headline outcomes from its trial of gepotidacin, an oral antibiotic aiming to address uncomplicated urogenital gonorrhoea in adolescents and adults, on Monday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.